Research
Hormonal
Liraglutide 1.8 mg/day reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality in patients with Type 2 Diabetes and high cardiovascular risk.
If you have Type 2 Diabetes and are at high risk for heart problems, adding a daily 1.8 mg liraglutide injection can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes, without increasing the risk of heart failure hospitalization.
StrongSupportsVERY_HIGH confidence
The LEADER trial noted that primary outcomes (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred less in the liraglutide group (608 out of 4668 (13.0%)) vs. placebo (694 out of 4672 (14.9%)) (hazard ratio (HR) 0.87; 95% CI 0.78–0.97; p = < 0.001 for non-inferiority; p = 0.01 for superiority).
Why this rating
Based on the large-scale LEADER trial (N=9340) with long-term follow-up (median 3.8 years).
Source
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Mariana Cornelia Tilinca et al. · Medicina · 2021
narrative_reviewCited 42×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →